
Innovation Pharma announced the next phase of Brilacidin Coronavirus testing begun
On May 5, 2020, Innovation Pharma reported it had executed a Material Transfer Agreement (MTA) with a leading U.S.-based Public Health Research Institute, with access to a Biosafety Level-3 (BSL-3) laboratory, to evaluate the immunomodulatory and antiviral properties of Brilacidin in relation to COVID-19. This new research is separate from the previously announced antiviral studies being conducted at a U.S. Regional Biocontainment Laboratory, which advanced to the next phase of Brilacidin testing.
Tags:
Source: Innovation Pharmaceuticals
Credit:
